ALPROLIX^®: the first EHL FIX
WITH >10 years OF REAL-WORLD EXPERIENCE^1–3

REDUCED BLEEDING AND IMPROVED JOINT HEALTH VS FIX ON-DEMAND¹³
Reinforcing the benefits of prophylactic factor treatment¹³

A retrospective review of six haemophilia treatment centres across the US for patients switching from previous FIX on-demand treatment to ALPROLIX prophylaxis reported:¹³

Numerical decrease in bleed rates¹³

ABRs improved numerically with ALPROLIX vs pre-switch FIX on-demand¹³

Median bleed rates pre- and post-switch: on-demand treatment to ALPROLIX prophylaxis (n=10)*¹³

Adapted from Shapiro A, et al. 2020¹³
p-value not reported

Improvements in joint health¹³

At the end of the chart review period,
32% (17/53)
of target joints had resolved¹³

47% (9/19) of patients did not report a target joint¹³

*Included patients with available ABR data pre- and post-switch to ALPROLIX prophylaxis.¹³
ABR, annualised bleeding rate; FIX, factor IX; IQR, interquartile range.

Specific adverse events that were collected and recorded during ALPROLIX
therapy included hypersensitivity (including anaphylaxis), nephrotic syndrome and
thrombosis/thromboembolism. Other adverse events were not collected in this review¹³

Reported safety outcome:

One patient experienced an AE of hypersensitivity,
which was not associated with inhibitor development¹³

AE, adverse event; FIX, factor IX.

*Primary objective: To understand the clinical characteristics and outcomes resulting from the real-world management of patients with haemophilia B being treated with ALPROLIX.¹³
ABR, annualised bleeding rate; FIX, factor IX.